All posts by imreal

G-CON and Just – Evotec Biologics Announce Project Installation


G-CON, prefabricated cleanrooms

G-CON PODs ready for installation at Just-Evotec in Toulouse, France

The combination of the PODs and cleanroom panels from G-CON Clean Solutions were seamlessly integrated by our teams for Just-Evotec Biologics, our first hybrid customer in Europe.

G-CON, the global leader in off-site prefabricated cleanroom systems, recently celebrated the arrival and start of the installation of PODs at Evotec’s Campus Curie in Toulouse, France. The Toulouse project is the first hybrid project for G-CON, delivering both PODs and G-CON Clean Solutions architectural systems. G-CON previously supplied the cleanroom PODs for the first J.POD facility at Just – Evotec Biologics’ site in Redmond, WA (US) in August 2021 where they have been performing process development and GMP clinical manufacturing for partners such as the U.S. Department of Defense.

“The combination of the PODs and cleanroom panels from G-CON Clean Solutions were seamlessly integrated by our teams for Just-Evotec Biologics, our first hybrid customer in Europe,” said Dr. Anne Jones, President and CEO of G-CON. “We are thrilled to partner with Just Evotec Biologics, where our combined products are integral to supporting the build out of their leading-edge manufacturing platform.”

Dr. Linda Zuckerman, Executive Vice President, Global Head Biotherapeutics at Just – Evotec Biologics, commented, “The installation of multiple cleanroom PODs by the G-CON team advances the construction of J.POD Toulouse, France (EU) significantly. The PODs are one of the cornerstones for our continuous manufacturing platform enabling advanced and efficient biomanufacturing processes available to our partners for the benefit of patients worldwide.”

About G-CON

G-CON specializes in the design and construction of advanced cleanroom solutions for a wide range of industries. G-CON works closely with customers and A&Es to provide solutions that meet their specific needs, building PODular cleanrooms offsite, and providing modular and hybrid construction options. These offerings enable rapid deployment and easy configuration of cleanrooms while delivering the highest quality facilities, quickly and on time and on budget as well. For more information visit http://www.gconbio.com.

About JUST – EVOTEC BIOLOGICS

Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at http://www.just-evotecbiologics.com.

For more information contact:

Brittany Berryman

Director of Marketing

G-CON Manufacturing, Inc.

6161 Imperial Loop, College Station, TX 77845

Phone: 979-431-0700

e-mail: bberryman@gconbio.com

http://www.gconbio.com

Share article on social media or email:

A-Alpha Bio Welcomes Heidi Hagen to Its Board of Directors


A-Alpha Bio

Her extensive experience as a biotechnology leader, founder, and operator will be instrumental in successfully developing our platforms, progressing our pipeline, and advancing A-Alpha Bio’s mission to improve human health by measuring and engineering protein-protein interactions.

A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio’s first independent board member.

Hagen has been a leader in the Biotechnology industry for 30 years. Over the course of her career, she has built an extensive track record in leading strategy and operations to progress innovative technologies from ideation to commercialization. Having been a core member of pharma companies like Vineti, Sotio, and Dendreon, Hagen intimately understands how pharma and biotech companies operate and scale from startup to global organization. Her experiences as a founder, C-Suite executive, and key operator in the growth and exits of numerous companies provide A-Alpha Bio with a wealth of valuable insights and lessons learned.

“We are thrilled to welcome Heidi to our Board of Directors,” said David Younger, CEO and Co-Founder of A-Alpha Bio. “Her extensive experience as a biotechnology leader, founder, and operator will be instrumental in successfully developing our platforms, progressing our pipeline, and advancing A-Alpha Bio’s mission to improve human health by measuring and engineering protein-protein interactions.”

Hagen has remained at the forefront of biotech innovation and business leadership with expertise spanning technical areas from protein therapeutics to cell therapies. Based in Seattle, Hagen will be on the ground to support and share her expertise and network with the A-Alpha Bio team.

“I am excited to join A-Alpha Bio’s Board of Directors and collaborate with this dynamic team of biologists, protein engineers, and data scientists,” said Hagen. “I believe that the convergence of machine learning and synthetic biology holds immense potential for advancing the development of novel therapeutics, particularly in the area of protein-protein interactions. Drawing from my diverse experiences in biotechnology, I am eager to work alongside A-Alpha Bio to achieve their goals and significantly impact human health.”

Hagen most recently served as Chief Technology Officer at Sonoma Biotherapeutics, an immune tolerance company engineering regulatory T cell (Treg) therapies to treat autoimmune and inflammatory diseases. Prior to that, she focused on precision medicine through her roles as the Co-Founder and former Chief Strategy Officer at Vineti, the Global Chief Operating Officer at Sotio, the Senior Vice President of Operations at Dendreon Corporation, and the Senior Manager of Supply Operations at Immunex Inc. In addition, Hagen serves as a board member and Governance Committee Chair for Obsidian Therapeutics and Vericel Corporation (NASDAQ:VCEL). Previously, Hagen also served on the boards of Alaunos Therapeutics and Lykan Biosciences.

Hagen earned her B.S. in cell and molecular biology, her M.S. in bioengineering, and her M.B.A all from the University of Washington, where her studies focused on the interaction between science and business.

For more information on A-Alpha Bio, please visit: https://www.aalphabio.com/.

About A-Alpha Bio

A-Alpha Bio uses synthetic biology and machine learning to measure, discover, predict, and engineer protein-protein interactions.

The company’s AlphaSeq platform applies synthetic biology to experimentally measure millions of protein-protein interaction affinities simultaneously. Protein binding data is incorporated into the company’s AlphaBind platform to train machine learning models that predict binding from sequence. A-Alpha Bio uses both platforms to discover and optimize high-impact therapeutics for their own pipeline and in partnership with industry leaders.

A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington’s Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/.

Share article on social media or email:

Benchmark Senior Living Debuts “Welcome Home” Campaign Touting Connected Lifestyle at 60 of Its Northeast Communities


Benchmark Senior Living “Welcome Home” Campaign

“Our communities aren’t just a place for older adults to live, they’re a place where everyone is connected and invested in seeing one another happy and engaged in what they enjoy.” -Tom Grape, founder, chairman and CEO of Benchmark

Today, Benchmark Senior Living, New England’s largest senior living provider with 65 independent living, assisted living, memory care assisted living and continuing care retirement communities throughout the Northeast, announced the debut of a new advertising campaign. The campaign, entitled Welcome Home, is designed to highlight the many ways in which Benchmark communities exceed expectations and enhance quality of life so that residents and their family members truly feel at home.

The multimedia campaign utilizes creative storytelling and impactful visuals to showcase the deep relationships formed within Benchmark communities and the special moments regularly shared between residents themselves and the passionate team that supports them. For example, the opportunity to begin one’s day with morning walks, enjoy chef-prepared meals, learn something new and end the day with concerts and dancing with people who care. Also, enjoy the little things that make life special like associates who truly know you.

“Our communities aren’t just a place for older adults to live, they’re a place where everyone is connected and invested in seeing one another happy and engaged in what they enjoy,” said Tom Grape, founder, chairman and CEO of Benchmark. “This campaign brings to life the true sense of home that Benchmark has provided to our residents, their families and our associates for more than 26 years.”

The outstanding care and experiences offered at Benchmark communities are made possible thanks to dedicated associates who are hired for heart and trained for skill. Associates are committed to fostering independence and nurturing residents’ passions and connections with care and personalized programs that keep them connected to who and what matters most in their lives.

Welcome Home launched today in major newspapers, online and social media.

The campaign was developed by Benchmark’s new creative agency of record, Boston-based Colossus. “A big reason we started Colossus was to choose our clients. Supporting Benchmark employees, who do incredible work that improves lives, fits our own values and we’re proud to be their partner,” said Colossus Managing Director, Jon Balck.

Colossus is an advertising and creative company partnering with like-minded brands who view creativity as a business lever. Their goal is to help brands break through the white noise of the mundane by shaping art, technology and commerce into meaningful experiences.

Benchmark senior assisted living communities offering independent assisted living and assisted living with memory care are located throughout Connecticut, Massachusetts, New Hampshire, Rhode Island, New York, Maine and Vermont. Benchmark Senior Living is also a respite care provider. Click here to learn more.

About Benchmark Senior Living

Benchmark is New England’s largest senior living provider with 65 independent living, assisted living, memory care and continuing care communities and over 5,000 dedicated associates providing compassionate care and outstanding experiences throughout the Northeast. The Waltham, Mass.-based company was founded over 25 years ago by Tom Grape with the purpose of Transforming Lives Through Human Connection. Since then, Benchmark has continued to set the industry standard, having won over a hundred local, regional and national awards for its care, programs and as a top workplace. Benchmark has been named one of the Top Places to Work for 15 straight years in The Boston Globe’s annual employee-based survey and received repeated recognition in FORTUNE’s Best Workplaces for Aging Services list. For more information, visit BenchmarkSeniorLiving.com.

Share article on social media or email:

Mount Sinai Institute for Exposomics Research Awarded $8.45 Million Grant to Study Environmental Health


“All diseases have both a genetic and environmental component, and we’re finding that the environmental contributions to most diseases are greater than the genetic contribution,” said Robert Wright, MD, MPH, Co-Director of the Institute for Exposomic Research.

The National Institute of Environmental Health Science (NIEHS) has awarded Mount Sinai’s Department of Environmental Medicine and Public Health and its Institute for Exposomics Research a new five-year P30 Center grant totaling $8.45 million to fund infrastructure that supports research on environmental exposures, including climate change, and their effects on health, disease, and development across the human lifespan.

The Institute for Exposomic Research at the Icahn School of Medicine at Mount Sinai is the world’s first institute to focus on exposomics. Exposomics is defined as the health impact of all the exposures an individual experiences in a lifetime. An individual’s exposome begins at conception and includes environmental, nutritional, social, physical, and occupational sources such as malnutrition, air pollution, social stressors, and chemicals. Researchers at the Institute will translate their findings into new strategies for prevention and treatment of diseases including autism, asthma, cancer, and chronic lung diseases that have an environmental component.

The grant will support studies on climate change, wildfire smoke, plastics and nanoparticles, air pollution, chemicals from consumer products, metals such as lead, and thousands of other environmental factors and their impacts on health.

“All diseases have both a genetic and environmental component, and we’re finding that the environmental contributions to most diseases are greater than the genetic contribution,” said Robert Wright, MD, MPH, Chair of the Department of Environmental Medicine and Public Health and Co-Director of the Institute for Exposomic Research. “In fact, genetics explains less than half of the cause of the most common diseases including cancer, obesity, asthma, Alzheimer’s disease, and many others; environmental factors explain the rest. When we factor in the environmental impact, we better understand the complete picture of how disease happens. This knowledge starts a domino effect, ultimately shaping how medicine is practiced and the messages we share with patients. The goal is to one day teach people how to modify their environment in ways that will have a profound impact on improved long-term health.”

The Institute paves the way via a global effort to advance exposomics research programs. The Institute has forged partnerships throughout the United States as well as in Europe, Latin America, and Asia, and has convened seven international exposome symposia to date. Most recently, symposia in Italy and Mexico brought leading scientists, clinicians, trainees, and policymakers together to advance the field and develop new collaborations. The next meeting, to be held in Nashville, Tennessee, will focus on maternal-child health and environmental justice in partnership with Meharry Medical College, January 22-24, 2024.

“Funding for research on the health impacts of our environment has exponentially increased in recent years,” said Rosalind Wright, MD, MPH, Dean for Translational Biomedical Research, Icahn Mount Sinai, and the Institute’s Deputy Director. “This grant allows us to continue paving the way in exposomics and dig even deeper into the effects of environment and health throughout the lifespan. Recent climate-related events are proving that now is the time to focus more funding on environmental factors on health. Unlike genetics, we can change our environments to prevent or alter the course, development, and disease.”

The NIEHS core centers support multidisciplinary research in environmental health and exposomics. Eligible institutions must demonstrate significant existing National Institutes of Health support for environmental research.

About the Mount Sinai Health System

Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.

Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report’s Best Hospitals, receiving high “Honor Roll” status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children’s Hospital among the country’s best in several pediatric specialties.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

The DRIPBaR is excited to announce the latest opening in Grand Rapids, MI on July 5, 2023!


To celebrate their arrival, The DRIPBaR Grand Rapids is offering 50% off any IV drip plus a FREE B12 Quick Shot when you book before July 5th!

The DRIPBaR is excited to announce the opening of its newest location in Grand Rapids, Michigan on July 5th, 2023. This marks the newest location for the franchise, with approximately 500+ additional locations in the pipeline.

The DRIPBaR Grand Rapids will offer all of the standard DRIPBaR services, including IV vitamin therapy and IM Quick Shots. This particular location will also offer a suite of additional wellness services – including Red Light Therapy, Oral Supplements, and Halotherapy, a cutting-edge new service that uses salt air to promote detoxification, improve respiratory health, and improve immune resilience.

Owned and operated by Rami Kassis, The DRIPBaR Grand Rapids is the newest location for the growing DRIPBaR franchise. Kassis, a D.O (Doctor of Osteopathic Medicine), is particularly excited about the immunity and anti-aging benefits of IV therapy. Along with the traditional IV drips and IM Shots, he is thrilled to offer additional services that address whole-body wellness – including Red Light Therapy, Oral Supplements, and Halotherapy, a cutting-edge new service that uses salt air to promote detoxification, improve respiratory health, and improve immune resilience.

He is excited to bring such cutting-edge wellness options to the community of Grand Rapids, as well as the surrounding areas of Byron Center, Lowell Charter Township, and Holland Heights.

Customers will have a variety of IV Lifestyle and IV Health Support Drips to choose from. All of these services are designed to help customers look and feel their very best, whether they are looking for a quick boost or a more long-term wellness solution. For those who don’t have time for a full vitamin infusion but want the benefit, clients can choose one of six IM Quick Shots that give the body an immediate boost.

To celebrate their arrival, The DRIPBaR Grand Rapids is offering 50% off any IV drip plus a FREE B12 Quick Shot when you book before July 5th. Appointments can be booked here!

About The DRIPBaR

Founded in 2016, The DRIPBaR is a nationwide franchise focused on helping people obtain their best physical and mental health using intravenous therapies.

Through advances in cellular and biological science, The DRIPBaR helps clients fight the consequences of chronic illness, address the effects of aging, and achieve balanced wellness. With a focus on ever-evolving treatments and medical advancements, the franchise hopes to shorten the gap between concierge and treatment-based medicine.

The DRIPBaR already has more than 600 additional locations in various stages of development across 28 states, with nearly 50 currently open and operating. For more information, visit their website.

The DRIPBaR Grand Rapids

2500 E Beltline Ave SE, Suite O-100

Grand Rapids, MI 49546

(616) 552-4903

grandrapids174@thedripbar.com

Share article on social media or email:

Light Chain Bioscience Chooses Genedata to Digitalize Cell Line & Bioprocess Development


News Image

Genedata Bioprocess allows us to keep track of our process development workflows and increases throughput to ensure that we develop efficient and scalable manufacturing processes for our proprietary drugs. Walter Ferlin, Ph.D., CSO at Light Chain Bioscience

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Light Chain Bioscience, a brand of Novimmune, has chosen the Genedata Bioprocess® enterprise platform to streamline and automate cell line and early bioprocess development of their lead candidates.

“With our pipeline of bispecific and multi-specific drug candidates rapidly growing, we needed a workflow management system that also captures all the data generated by our CDMOs and integrates them with our in-house experimental results. Genedata Bioprocess allows us to keep track of our process development workflows and increases throughput to ensure that we develop efficient and scalable manufacturing processes for our proprietary drugs,” said Walter Ferlin, Ph.D., CSO. “Being able to integrate the system with Genedata Biologics®, our existing biologics discovery workflow platform, also gives us company-wide access to both research and development data in one shared platform, which is so valuable because we can trace everything — all the way back from manufacturing through development to initial candidate selection,” said Nicolas Fischer, Ph.D., CEO at Light Chain Bioscience.

Light Chain Bioscience focuses on the development of innovative therapies using their proprietary technologies to discover and develop bispecific and multi-specific therapeutic antibodies that fully retain the native sequence and structure of human antibodies. Genedata Bioprocess is fully integrated with Genedata Biologics and supports the entire end-to-end development process at Light Chain Bioscience across CLD, USP, DSP, and analytics operations.

Co-developed over the last ten years with major biopharmaceutical companies, Genedata Bioprocess has been adopted by multinational biopharmaceuticals as well as innovative biotech companies, especially in the RNA and cell & gene therapy space. The platform integrates all data generated along the biotherapeutics development and CMC process, including cell line development, upstream, downstream, and analytics functions. It enables fully automated processes, such as streamlining highly parallelized scale-down expression experiments with mini-bioreactors. In addition, by providing an integrated platform across research and development, it accelerates and improves the drug candidate transition from research to development. Built on a modular and scalable architecture, the system is suitable for installations ranging from single-site groups to global, multi-site biopharma development organizations.

“We are delighted to see Light Chain Bioscience expanding their usage of the Genedata Biopharma Platform to now integrate both their discovery and development operations,” said Othmar Pfannes, Ph.D., CEO of Genedata. “We have identified the R2D transition as one of the main bottlenecks in the biopharma industry. We are pleased to see that our integrated R&D workflow platform helps our customers to overcome this challenge by reducing process complexity, automating operations, streamlining data exchange with CDMOs, and ultimately, increasing efficiency.”

About Light Chain Bioscience

Light Chain Bioscience is a clinical-stage company focused on the discovery and development of therapies based on bispecific and multi-specific antibody formats. Its proprietary κλ body platform allows for the identification of bispecific antibodies that fully retain the native sequence and structure of human antibodies. This unique property is of interest for long term treatment of patients. In immuno-oncology, Light Chain Bioscience focuses on the selective targeting of the checkpoint CD47 as well as T cell and activation redirecting strategies.

http://www.lightchainbio.com

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.

http://www.genedata.com

LinkedIn | Twitter | YouTube

Contact

Allison Kurz

Genedata

Public Relations

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:



The Prem Rawat Foundation Feeds Children in South Africa


A member of The Prem Rawat Foundation team visits the Gogo Kitchen project.

Providing humanitarian aid is a key part of Prem Rawat’s vision for TPRF, which he founded in 2001 to help people live in dignity, peace and prosperity by addressing fundamental human needs.

“We cannot fully express our gratitude to The Prem Rawat Foundation for your support and care. We are so excited that now we can grow our daily reach thanks to your support, providing the children with more nutritious meals and a safe place.” – Leanne Lorrance, Likhon iThemba Director

A partnership between The Prem Rawat Foundation (TPRF) and Likhon iThemba, a local nonprofit that means “there is hope” in the Zulu language, began last year in the wake of torrential floods that devastated disadvantaged communities in Durban, South Africa.

To help people recover, TPRF distributed $48,000 in grants to five local organizations, including Likhon iThemba, to provide food, water and shelter. The initial aid was greatly appreciated but the floods aggravated ongoing local challenges. A new TPRF grant of $8,000 will help Likhon iThemba expand the Gogo Kitchen project, feeding children who often suffer from malnutrition and HIV.

“Gogo” means “grandmother” in Zulu and the kitchens are staffed by beloved local elders. The modest new TPRF grant will go a long way, enabling the Gogo program to serve 120 children nutritious meals five to seven days a week, doubling the current amount of three meals per week that they are able to provide. Likhon iThemba also provides a safe place for children after school where they can do homework, stay off the streets and receive adult mentorship.

The three Gogo Kitchens serve disadvantaged neighborhoods which have some of the highest rates of HIV in the world. Many children take HIV medication and if the medication is taken on an empty stomach, they get sick. At the kitchens, the children are able to take their medication on a full stomach after their meals. Likhon iThemba also runs homes for abandoned infants and disabled children.

“We cannot fully express our gratitude to The Prem Rawat Foundation for your support and care for our program. We at Likhon iThemba are continually inspired by the dedication and generosity of donors like yourself who answer the call to give again and again. We are so excited that now we can grow our daily reach thanks to your support, providing the children with more nutritious meals and a safe place,” says Leanne Lorrance, Likhon iThemba Director.

“I am personally touched by this Gogo program and I’m struck by how similar it is to the Food for People program,” says Marcia Leitner, TPRF Executive Director. “Thank you to all of the TPRF donors who make meaningful work like this possible. You are touching hearts and changing lives.”

Food for People is a signature TPRF program that has similarly helped empower people in critical need by providing over 5.2 million meals and crisis relief in India, Nepal and Ghana.

Providing humanitarian aid is a key part of Prem Rawat’s vision for TPRF, which he founded in 2001 to help people live in dignity, peace and prosperity by addressing fundamental human needs.

Last year he met with Durban officials to determine how to best help flood victims and discuss his approach to helping each other through hard times. “The Prem Rawat Foundation prides itself on getting the help to those people who truly need it,” said Mr. Rawat.

Prem Rawat recently completed a tour of South Africa to help address people’s fundamental need for peace. At events throughout the country he highlighted the Peace Education Program, providing practical guidance on how to experience personal peace by looking within and getting in touch with your heart.

Prem Rawat’s Peace Education Program, administered by TPRF, is growing in popularity across South Africa and the world by giving participants the opportunity to focus and reflect on their own humanity and their inner resources such as choice, hope and dignity. Over 300,000 people in more than 80 countries have participated in the program, including over 26,000 people in South Africa. Many report profound benefits such as enhanced self-awareness, tolerance and contentment.

Share article on social media or email:

Study shows lifestyle intervention promoting whole-food, plant-predominant eating pattern can achieve type 2 diabetes remission


News Image

This case series further supports the effectiveness of a whole-food, plant-predominant eating pattern as a primary intervention to achieve remission.

A lifestyle-based treatment intervention promoting adherence to a whole-food, plant-predominant eating pattern and integrated into routine care can successfully achieve type 2 diabetes remission, according to a research study published in the American Journal of Lifestyle Medicine.

The case series determined that a sample of 59 patients from a cardiac wellness program, who also had type 2 diabetes, achieved significant improvements in blood glucose control, and in 37 percent of cases, full remission of their diabetes. The patients were treated with a low-fat, whole-food, plant-predominant dietary pattern while also receiving standard medical treatment at a wellness center in Virginia. Improvements in glucose control were accompanied by significant reductions in BMI.

Previous studies have demonstrated that whole-food, plant-predominant eating patterns can improve diabetes outcomes but that research primarily involved substantial calorie restriction, often relying on liquid meal replacements, or fasting. This study, published in collaboration with the American College of Lifestyle Medicine (ACLM), is unique in its assessment of remission as a primary outcome and contributes novel information on the feasibility of achieving remission simply by eating healthy food.

“The prevalence of diabetes is growing, as is recognition in the health care community that diet as the primary intervention can achieve lasting remission in individuals with type 2 diabetes,” said Gunadhar Panigrahi, MD, FACC, DipABLM, the first author of the study. “This case series further supports the effectiveness of a whole-food, plant-predominant eating pattern as a primary intervention to achieve remission as well as the need for increased education for both clinicians and patients on the successful application of lifestyle medicine principles and dietary interventions in everyday medical practice.”

Researchers reviewed electronic health records of patients treated at the wellness clinic between 2007 and 2021 to identify those who adopted a whole-food, plant-predominant eating pattern and achieved meaningful improvements in HbA1c or blood glucose control, as well as remission of type 2 diabetes. Data points were extracted from the periods immediately before the lifestyle intervention and the most recent post intervention.

The study used the 2022 consensus definition of remission published by ACLM of HbA1c less than 6.5% for at least three months without surgery, devices, or active pharmacologic therapy to lower blood glucose. That expert consensus statement was endorsed by the American Association of Clinical Endocrinology, supported by the Academy of Nutrition and Dietetics and co-sponsored by the Endocrine Society.

The mean age of the patients was 71.5 years and ranged in age from 41 to 89 years. Twenty-two of the 59 patients met the criteria for type 2 diabetes remission. The study also reported an average de-escalation of glucose-lowering medications among patients following lifestyle change. The reduction in glucose-lowering medications was consistent with that mentioned in a recent qualitative case series that provided the first published examples of protocols to help guide clinical decision making on when and how to deprescribe medications following lifestyle intervention. Medication deprescribing is a process that is supervised by a physician when a medication is no longer benefiting a patient.

The study highlighted that many patients did not first self-select into a lifestyle medicine treatment program for type 2 diabetes, but were rather educated on the merits of a whole-food, plant-predominant dietary pattern and regular physical activity as part of their routine care at the wellness center.

“There is a perception that many patients may not accept the idea of adopting a whole-food, plant predominant eating pattern but there is a growing abundance of research that in fact shows adherence to a plant-predominant dietary pattern is feasible, and even enjoyable,” said Micaela Karlsen, ACLM Senior Director of Research. “Although full remission may not be possible for every patient, our research shows that every patient deserves to know that it may be possible through the adopting of appropriately dosed therapeutic lifestyle change.”

Future research should measure the proportion of patients in typical medical practices who are willing to consider lifestyle changes as part of routine treatment and examine the factors leading to successful implementation of a plant-predominant dietary intervention, the authors said.

ABOUT ACLM

The American College of Lifestyle Medicine is the nation’s medical professional society advancing lifestyle medicine as the foundation for a redesigned, value-based and equitable healthcare delivery system, leading to whole person health. ACLM educates, equips, empowers and supports its members through quality, evidence-based education, certification and research to identify and eradicate the root cause of chronic disease, with a clinical outcome goal of health restoration as opposed to disease management.

Share article on social media or email:

A High-Performance Face Authentication OEM Solution


Alcatraz AI, a global leader in autonomous access control solutions, unveils the Rock embedded module, Rock M, a groundbreaking facial authentication OEM solution designed for extreme reliability, improved throughput, and security using cutting-edge artificial intelligence (AI) technology with advanced features. The module offers unmatched accuracy and enhanced performance for a wide range of applications, where dependable facial authentication was not possible before.

With Rock M, Alcatraz AI brings to the market a secure facial authentication module that leverages revolutionary hardware, powerful software, and algorithms cultivated through meticulous research and development. By incorporating pioneering patented technologies, Alcatraz AI ensures a level of performance and reliability that surpasses industry standards. Built with a next-generation AI GPU/NPU, the Rock M harnesses the power of its Quad-core ARM Cortex A76 and A55 processors, providing a generational leap in processing capabilities. Combined with leading-edge optics, the module provides unparalleled operation in diverse lighting conditions and environments, offering simplified deployment and versatility. The Rock M excels in any scenario, reliably authenticating at 0-120k lux (total darkness to the brightest possible sunlight outdoors) with temperature range of -40°C to 66°C (-40°F to 150°F), guaranteeing high performance even in extreme weather conditions.

Setting new standards in facial authentication, the Rock M boasts an extended range of up to two meters (6.5 feet), employing both 2D and 3D sensors to enable liveness detection and effectively counter spoofing attempts at PAD Level 2, even under the most challenging lighting conditions. This groundbreaking solution allows OEMs to easily add facial authentication to their products. Its applications span various industries, including access control devices, time and attendance terminals, smart customer management kiosks, data centers, ATMs, vending machines, door locks, automotive systems, ticketing stations and IoT environments.

Organizations can integrate the Rock M into their devices to:

Enhance speed and efficiency – Facial authentication technology ensures faster throughput or authentication, working seamlessly in all environments. It eliminates issues that cause false rejections by consistently capturing high-quality facial images even in challenging conditions such as low light, variations in facial appearance, and aging.

Ensure accurate identification – With reliable 1:1 and 1:N matching capabilities, organizations can be confident that only legitimate users will be authenticated. Alcatraz AI’s advanced facial authentication technology delivers precise matching accuracy, minimizing the risk of false positives or false negatives.

Optimize space utilization -The Rock M features a compact design perfectly suited for space-constrained applications. By integrating facial authentication into their devices, organizations can reduce their physical footprint while maintaining robust authentication capabilities.

“We are excited to introduce the Rock M as a game-changing innovation in face authentication technology,” said Tina D’Agostin, CEO at Alcatraz AI. “Our mission is to empower businesses to create highly advanced, contactless, and secure solutions. The Rock M not only delivers exceptional performance but also reinforces our commitment to accelerating the adoption of state-of-the-art AI biometric solutions.”

Alcatraz is currently pursuing joint ventures with leading hardware manufacturers. For more information about the Rock M and Alcatraz AI’s portfolio of innovative solutions, please visit here: https://alcatraz.ai/rock-m

About Alcatraz AI

Founded in 2016, Alcatraz AI is the most secure, effective, comprehensive access control biometric solution on the market. With its patented technology, Alcatraz AI’s facial authentication technology and intelligent tailgating detection work natively with existing access control systems to transform physical security. With a vision of simplicity and security, Alcatraz AI protects more than one million employees at Fortune 500 companies, including their assets and secure facilities.

For more information, please visit http://www.alcatraz.ai and follow @alcatrazai on Twitter and Alcatraz on LinkedIn.

Contact

Linda Ebrahimian

Director of Corporate Marketing at Alcatraz AI

linda@alcatraz.ai

###

Share article on social media or email:

WellnessEvidence.com Adds CBD to Its Growing List of Wellness Approaches with Aim of Empowering Consumers to Make More Informed Decisions


News Image

WellnessEvidence.com is a ‘spin-free’ research zone where you can research studies for CBD, whether positive or negative. Because more knowledge always means more empowerment

The nonprofit Global Wellness Institute™ (GWI), the leading research and educational resource for the global wellness industry, reminds wellness seekers that there is evidence-based medical research available on most mainstream wellness modalities – whether that evidence is good, bad or inconclusive.

“WellnessEvidence.com provides direct access to the universe of clinical studies for common wellness modalities–at the databases that doctors use–to help consumers, medical professionals, the wellness industry, and the media dive into the actual evidence (or lack thereof) for that approach,” said Susie Ellis, chair and CEO of the GWI.

“CBD, a non-psychoactive part of the cannabis sativa plant, has recently soared in popularity and has seen a lot of marketing hype as a cure-all. While studies are increasing, unlike the overwhelmingly positive evidence for approaches such as exercise or healthy sleep, the evidence around CBD can be complex and confusing,” continued Ellis. “There are too many small trials with conflicting results as well as trials and metareviews that too often include THC/CBD compounds rather than studying just pure CBD.

WellnessEvidence.com is a ‘spin-free’ research zone where you can research studies for CBD, whether positive or negative. Because more knowledge always means more empowerment.”

WellnessEvidence.com provides free and easy access to the studies on wellness approaches at the world’s most authoritative sources of evidence-based medicine, including the Cochrane Library, PubMed and the TRIP Database–in just a click or two you can explore dozens, sometimes hundreds or thousands, of studies. The site also provides summaries of representative studies, as well as the current clinical trials underway for that wellness approach.

The new platform for CBD lets people research some key questions:


  • Does CBD improve sleep? A small, randomized, double-blind, placebo-controlled 2022 study from Australian researchers tested medicinal cannabis oil containing THC and CBD and found that it improved sleep quality and quantity, increasing levels of the sleep hormone melatonin by 30%; while a larger 2023 study from UCLA and Scripps Clinic Sleep Center found that low doses of CBD improved sleep quality in patients with a history of sleep disturbances.
  • Does CBD help with pain relief? A large 2017 report concluded that substantial evidence exists for cannabis plus cannabinoid treatment for three conditions: chronic pain, chemotherapy-induced vomiting and muscle spasms; however CBD alone may not be as effective in pain treatment, with a separate 2022 study finding that 28 days of CBD oil application did not reduce symptoms of distress and pain for patients with advanced cancer.
  • Can CBD help with anxiety and other mental health conditions? A 2019 metareview indicates that there is a promising, yet unproven, role for CBD in managing anxiety disorders; while a much larger 2019 metareview published in The Lancet looked at ways CBD impacts a number of mental health conditions – including depression, anxiety, ADHD, Tourette syndrome, PTSD and psychosis – finding “scarce evidence.”

Other recent additions to WellnessEvidence.com include psilocybin, halotherapy and complementary and alternative medicine (CAM) for cancer. To access the medical evidence for the 33 featured wellness approaches, visit http://www.wellnessevidence.com.

About the Global Wellness Institute: The Global Wellness Institute (GWI), a nonprofit 501(c)(3), is considered the leading global research and educational resource for the global wellness industry and is known for introducing major industry initiatives and regional events that bring together leaders to chart the future. GWI positively impacts global health and wellness by educating public institutions, businesses and individuals on how they can work to prevent disease, reduce stress, and enhance the overall quality of life. Its mission is to empower wellness worldwide.

Share article on social media or email: